Barr Pharmaceuticals Inc. and the U.S. Food and Drug Administration are scheduled to meet Tuesday to discuss the company’s bid to sell its morning-after contraceptive Plan B without a prescription, the agency said on Wednesday.
Barr Pharmaceuticals Inc. and the U.S. Food and Drug Administration are scheduled to meet Tuesday to discuss the company’s bid to sell its morning-after contraceptive Plan B without a prescription, the agency said on Wednesday.
